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Abstract
Objectives. Complete deficiency of alternative pathway (AP)
complement factors, explained by homozygous mutations, is a
well-known risk factor for invasive bacterial infections; however,
this is less obvious for heterozygous mutations. We describe two
siblings with a heterozygous NM_001928.3(CFD):c.125C>A
p.(Ser42*) mutation in the complement factor D (fD) gene having
a history of recurrent bacterial infections. We determined the
effect of heterozygous fD deficiency on AP complement activity.
Methods. We determined the effect of fD levels on complement
activation as measured by AP activity, complement C3 binding to
the bacterial surface of Neisseria meningitidis (Nm), Streptococcus
pneumoniae (Sp) and non-typeable Haemophilus influenzae
(NTHi), and complement-mediated killing of Nm and NTHi. In
addition, we measured the effect of vaccination of complement
C3 binding to the bacterial surface and killing of Nm. Results.
Reconstitution of fD-deficient serum with fD increased AP activity
in a dose- and time-dependent way. Reconstitution of patient
serum with fD to normal levels increased complement C3 binding
to Sp, Nm and NTHi, as well as complement-mediated killing of
Nm and NTHi. Vaccination increased complement C3 binding and
resulted in complete killing of Nm without fD reconstitution.
Conclusion. We conclude that low fD serum levels (< 0.5 lg mL1)
lead to a reduced speed of complement activation, which results
in diminished bacterial killing, consistent with recurrent bacterial
infections observed in our index patients. Specific antibodies
induced by vaccination are able to overcome the diminished
bacterial killing capacity in patients with low fD levels.
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INTRODUCTION
One of the first defence barriers after bloodstream
invasion of bacteria is complement activation,
leading to the covalent fixation of opsonising C3b
molecules on the bacterial surface and, in case of
Gram-negative bacteria, to killing by the insertion
of the membrane attack complexes (MAC) in the
bacterial outer membrane.1 However, these
processes will only be protective when they start in
time and when they run fast enough to keep the
exponential outgrowth of bacteria in control.
While the lectin pathway (LP) and the classical
pathway (CP) direct the site of complement
activation to the bacterial surface, the alternative
pathway (AP), sometimes called ‘Amplification
Pathway’, is designed to accelerate the process of
complement activation by generation of C3b that is
both a product of AP-convertase activity and the
starting point for new and more AP-convertase
complexes. Absent AP activation, as occurs for
instance in patients with Properdin or factor D (fD)
deficiency, is associated with invasive
meningococcal infections with a rapid and
overwhelming outgrowth of bacteria in the
bloodstream.2–9 Apparently, complement
activation in these conditions is too slow to control
the growth of the bacteria.
Complete fD deficiency is a rare but well-
recognised cause of a defective AP complement
activation that predisposes to overwhelming
bacterial infections. Up till now, heterozygous
mutations in the fD gene were not regarded as
clinically important. In the present study, we present
two siblings with low serum fD concentrations
explained by a heterozygous NM_001928.3(CFD):
c.125C>A p.(Ser42*) mutation. By measuring the AP
activity, C3b fixation and bactericidal activity in the
sera with low fD concentrations and in fD-deficient
serum supplemented with various concentrations of
purified fD, we provide evidence that low fD
concentrations (< 0.5 µg mL1) results in a slower
complement activation speed and bactericidal
activity. These findings point towards novel type of
immunodeficiency, that is characterised by an intact
but too slow complement response, which
predisposes to infections with rapidly proliferating




Patient A was referred to our hospital at the age of
11 because of recurrent infections. His medical
history revealed recurrent acute otitis media in the
first 2 years of life. At 2 years of age, he suffered
from a Staphylococcus aureus septic coxarthritis
with bacteraemia, requiring intravenous
flucloxacillin, with full recovery. At ages 2 and 9, he
was diagnosed with bacterial pneumonia and
received out-patient antibiotic treatment. At the
age of 11, he developed mastoiditis caused by
Streptococcus pyogenes treated with intravenous
ceftriaxone. He received all the childhood vaccines,
including 10-valent conjugate pneumococcal
vaccine, Haemophilus influenzae type B and group
C Meningococcus vaccine.
Immunological evaluation showed normal
immunoglobulin levels and a normal response to
pneumococcal polysaccharide vaccination.
Evaluation of his complement status demonstrated
a decreased AP of 50% (reference 67–133%), a
normal CP of 114% (reference 67–149%) and a
decreased serum concentration of fD 0.26 µg mL1
(reference 0.96–2.13 µg mL1). Analysis of 34
complement proteins in serum by mass
spectrometry revealed undetectable fD and
significant lower C1 inhibitor, C3, C5 and vitronectin
serum level.10 Genetic analysis of complement
genes revealed a maternal heterozygous
NM_001928.3(CFD):c.125C>A p.(Ser42*) gene
mutation. Additional analysis of 386 primary
immunodeficiency genes using clinical exome
sequencing was further normal. Following
diagnosis, he was started on co-trimoxazole
prophylaxis and received additional meningococcal
ACYWand 4C-MenB vaccines.
Patient B was the only sister of patient A and was
also diagnosed with complement fD deficiency
(Heterozygous NM_001928.3(CFD):c.125C>A
p.(Ser42*) mutation in the fD gene) at the age of 6.
Until then, she suffered from recurrent acute otitis
media and sinusitis, but had no history of severe
bacterial infections. Complement evaluation
demonstrated a decreased AP of 53% (reference 67–
133%), a normal CP of 89% (reference 67–149%)
and a decreased serum fD level of 0.30 µg mL1
2021 | Vol. 10 | e1256
Page 2
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
Australian and New Zealand Society for Immunology, Inc.
Factor D and complement activation speed JD Langereis et al.
(reference 0.96–2.13 µg mL1). Analysis of 34
complement proteins in serum by mass
spectrometry revealed undetectable fD.10 Genetic
analysis of complement genes demonstrated the
familial heterozygous fD mutation. Following
diagnosis, she was started on co-trimoxazole
prophylaxis and received additional pneumococcal,
meningococcal ACYWand 4CMenB vaccines.
Complement factor D haplodeficiency
results in decreased complement binding
and complement-mediated killing
In order to determine the functional consequences
of the lowered fD serum levels in our two patients,
we reconstituted patient serum with purified fD up
to 2.0 µg mL1 and determined complement
activity and complement-mediated killing of Gram-
positive Streptococcus pneumoniae (Sp) and Gram-
negative Neisseria meningitidis (Nm) and non-
typeableH. influenzae (NTHi) bacteria.
Reconstitution of patient serumwith fD increased
binding of C3 to the bacterial surface of Nm, Sp and
NTHi (Figure 1a). Consistent with increased C3
binding to the bacterial surface as read-out for
complement activation, reconstitution of patient
serum with fD increased direct complement-
mediated killing of Nm and NTHi (Figure 1b).
Neisseria meningitidis vaccination
compensates for decreased complement
activity in patient serum
We determined the effect of meningococcal
ACYW and 4CMenB vaccination on complement
activity and complement-mediated killing of Nm
strains using serum of both patient A and B
sampled before and 5 months post-vaccination. As
expected, following vaccination, binding of IgG to
the bacterial surface of Nm with post-vaccination
serum was significantly higher than that with pre-
vaccination serum (Figure 2a). Binding of C3 to
the bacterial surface of Nm with post-vaccination
serum was significantly higher than that with pre-
vaccination serum (Figure 2b) for both patients. In
addition, vaccination resulted in almost complete
killing of Nm strains (Figure 2c).
Complement factor D increases complement
activation speed in a dose-dependent way
To determine the effect of fD serum level on the
speed of complement activation, we reconstituted
serum from a fD-deficient patient with purified
fD. In order to capture complement activation
speed, we determined the formation of the C5b-9
complex after 30, 45, 60 and 75 min of incubation
with fD-deficient serum, fD reconstituted serum or
pooled human serum as control. The CP was not
affected by the absence of fD, nor by fD
reconstitution (data not shown). In contrast, no
activation of the AP was observed using fD-
deficient serum, and reconstitution of fD dose-
dependently increased AP activation (Figure 3a),
reaching normal levels (AP > 67%, dotted
horizontal line) with 0.5, 1.0 and 2.0 µg mL1
purified fD, and a maximum activity with
2.0 µg mL1 purified fD of 86% compared to
normal serum (Figure 3b). Wieslab AP ELISA also
showed no activity for fD deficient serum, and
reconstitution of fD increased AP activation in a
dose-dependent manner (Figure 3c). However, the
maximum AP activity with 2.0 µg mL1 purified fD
in the Wieslab ELISA was lower than (71%) the
maximum AP activity in our AP activity assay
(86%). The difference in maximum AP activity
with 2.0 µg mL1 purified fD is largely due to a
higher complement activity of the positive control
compared to normal serum, which shows 85%
activity compared to the positive control in the
Wieslab AP ELISA.
The speed of AP activation, as measured by the
slope between time-points 45 and 75 min, also
increased in a fD dose-dependent way (Figure 3c).
Of note, the speed of AP activation was highly
correlated (R2 = 0.9923, P-value < 0.0001) with the
AP percentage as measured after 75 min
(Figure 3d), indicating that the AP percentage is a
reliable tool to estimate the speed of AP
complement activation. The half maximal effective
concentration (EC50) of fD on the speed of AP
activation was 0.24 µg mL1 (R2 = 0.9933)
(Figure 3e), which is consistent with an AP of
~50% for Patient A and Patient B having
~0.3 µg mL1 fD.
Complement factor D increases complement
C3 deposition on the bacterial surface in
dose-dependent way
Next, we determined the effect of reconstituting
fD-deficient serum with purified fD on
complement deposition on the bacterial surface
of bacterial pathogens Nm, Sp and NTHi. Binding
of complement C3 to the bacterial surface of Nm,
Sp and NTHi was time- and fD-concentration
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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dependent (Figure 4). The speed of complement
activation, as measured by the increase in slope
between time-points 5 and 15 min compared to
no fD, increased in a fD dose-dependent manner
with an EC50 of 0.09, 0.17 and 0.16 µg mL1 fD
for Nm, Sp and NTHi, respectively. These results
show that the level of fD, and thereby the speed
of complement activation, has a major effect on
the clearance of rapidly proliferating bacteria.
DISCUSSION
Here, we demonstrate that a heterozygous
NM_001928.3(CFD):c.125C>A p.(Ser42*) mutation
in the fD gene can result in lower serum fD levels
(~0.3 µg mL1), evolving in a slower speed of AP
complement activation and thus in a higher
chance to acquire bacterial infections.
factor D deficiency is a rare condition with only
six previously published case reports. The first
publication of Kluin-Nelemans from 1984
described a partial fD deficiency in a 40-year-old
monozygous twin with upper and lower
respiratory tract infections caused by
H. influenzae, Proteus mirabilis and Pseudomonas
aeruginosa since childhood.2 In 1989, Hiemstra
et al. described a young man with complete fD
deficiency, who had a N. meningitidis meningitis
at the age of 14 and episodes of invasive Neisseria
gonorrhoeae disease at the age of 19 and 24.3
Complete deficiency was also reported by Weiss
et al. in 1998, in a 6-day-old baby with
S. pneumoniae meningitis and sepsis.4 The first
genetically confirmed case series dates from
2001,5 which described five family members of a
highly consanguineous Dutch family with
(a)
(b)
Figure 1. Reconstitution of patient serum with purified factor D increases complement C3 binding to the bacterial surface and complement-
mediated killing. (a) N. meningitidis serogroup B strain H44/76 (MenB) (n = 6), N. meningitidis serogroup C strain C11 (MenC) (n = 6),
S. pneumoniae strain PBCN0460 (Sp 0460) (n = 4), S. pneumoniae strain TIGR4 (Sp TIGR4) (n = 4), NTHi strain 11P6H (n = 4) and NTHi strain
86-028NP (n = 4) were incubated with 10% patient serum in HBSS3+ with and without factor D reconstitution for 30 min at 37°C, and binding
of C3 to the bacterial surface was determined by flow cytometry. (b) N. meningitidis serogroup B strain H44/76 (MenB) (n = 6), N. meningitidis
serogroup C strain C11 (MenC) (n = 6), NTHi strain 11P6H (n = 4) and NTHi strain 86-028NP (n = 4) were incubated with 20% (N. meningitidis)
or 5% (NTHi) patient serum with and without factor D reconstitution for 60 min at 37°C, and the number of bacteria was determined by colony-
forming unit (CFU) counts. A two-tailed paired t-test was performed to determine statistical significance. NS, not significant; *P-value < 0.05;
**P-value < 0.01.
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complete fD deficiency with the same, but in this
case homozygous mutation as found in our study
(NM_001928.3(CFD):c.125C>A p.(Ser42*)). Two of
these fD-deficient individuals suffered from
invasive meningococcal disease at the age of 23
and 20, the latter died at the age of 71 from a
fatal S. pneumoniae pneumonia and meningitis.
In 2006, our group reported on two Turkish
babies, a girl of 9 months and her brother of
13 months old, both with severe invasive
meningococcal disease and complete fD deficiency
due to a double homozygous mutation.6 At last in
2018, Sng et al. reported invasive meningococcal
disease in a 19-year-old South Asian female with a
type III fD deficiency; her younger brother had
the same mutation but no disease.7 From these
studies, describing 11 cases of complete fD
deficiency, it can be concluded that fD deficiency
may cause disease at any age. However,
demonstrated by the identification of four
affected healthy sibs with complete fD deficiency,
the defect by itself does not influence normal
childhood development, provided there is no
contact with a virulent bacterial strains.
A second conclusion that can be drawn is that
incomplete fD deficiency present in several family
members carrying the heterozygous mutation
does not predispose to increased susceptibility for
infections. In three studies,3,5,6 24 family members




Figure 2. Vaccination increases complement C3 binding to the bacterial surface and killing of N. meningitidis. (a) N. meningitidis serogroup B
strain H44/76 (MenB) (n = 6) and N. meningitidis serogroup C strain C11 (MenC) (n = 3) were incubated with patient pre- and post-vaccination
serum in HBSS3+ for 30 min at 37°C, and binding of IgG to the bacterial surface was determined by flow cytometry. (b) N. meningitidis
serogroup B strain H44/76 (MenB) (n = 6) and N. meningitidis serogroup C strain C11 (MenC) (n = 6) were incubated with patient pre- and post-
vaccination serum in HBSS3+ for 30 min at 37°C, and binding of C3 to the bacterial surface was determined by flow cytometry. (c)
N. meningitidis serogroup B strain H44/76 (MenB) (n = 6) (20% serum in HBSS3+) and N. meningitidis serogroup C strain C11 (MenC) (n = 6)
were incubated with 20% (MenB) or 5% (MenC) patient pre- and post-vaccination serum in HBSS3+ with and without factor D reconstitution for
60 min at 37°C, and the number of bacteria was determined by colony-forming unit (CFU) counts. The horizontal dotted line represents the
lower limit of detection. A two-tailed paired t-test was performed to determine statistical significance. NS, not significant; *P-value < 0.05; **P-
value < 0.01; ***P-value < 0.001.
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levels; none had a history of infections. However,
fD concentration in most carriers was rather high;
Biesma measured in 19 carriers a mean of
0.92  0.24 µg mL1,5 while fD levels in the family
members without the mutation was
2.22  0.68 µg mL1, which was higher in
comparison to 60 non-related healthy donors
(1.39  0.32 µg mL1). Of note, the fD-gene
mutation in the Biesma study was similar to the
mutation as found in our study. Therefore, it
appears that because of interindividual variability,
some individuals with a heterozygous mutation
will demonstrate lower complement fD serum
levels, while others with the same mutation will
have normal complement fD serum levels. Kluin-
Nelemans, the first publication on partial fD
deficiency, reported a lowered fD level of 8%,
that is between 0.08 and 0.17 µg mL1 with a
normal range of 0.96–2.13 µg mL1.2 The two




Figure 3. Reconstitution of factor D-deficient serum with purified factor D increases complement activation speed in a dose-dependent way.
Factor D-deficient serum was reconstituted with purified factor D, and (a) C5b-9 formation was determined by ELISA after 30, 45, 60 and
75 min (n = 3). (b) AP was calculated at 75 min (the horizontal dotted line visualises AP of 67%), (d) and AP activation speed as determined by
the slope between 45 and 75 min. (c) Factor D-deficient serum was reconstituted with purified factor D, and AP activity was determined by
Wieslab ELISA. (e) Linear regression between AP and AP activation speed was calculated. (f) One-phase decay non-linear fit between AP
activation speed and serum factor D concentration. The vertical dotted line visualises the EC50.
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Figure 4. Reconstitution of factor D-deficient serum with purified factor D increases complement deposition on the bacterial surface in a time-
and dose-dependent way. (a) N. meningitidis serogroup C strain C11 (n = 4), (b) S. pneumoniae strain TIGR4 (n = 4) and (c) NTHi strain 11P6H
(n = 3) were incubated with 10% factor D-deficient serum in HBSS3+ with or without reconstitution of purified factor D for 5, 15 and 30 min at
37°C, and binding of C3 to the bacterial surface was determined by flow cytometry. One-phase decay non-linear fit between C3 binding rate
and serum factor D concentration was calculated. The vertical dotted line visualises the EC50.
ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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clinical picture with recurrent infections as
compared to our two patients.
Recently, we have determined serum levels of
34 complement proteins in 40 healthy controls, 83
patients with a diagnosed deficiency and 14
individuals with a potential pathogenic variant.
Among the patients, three patients with a
heterozygous NM_001928.4(CFD):c.744C>G
p.(Ile248Met) mutation were included. For all
three patients, a lower fD serum level was found,
but no clinical presentation or history of these
patients was available.
Despite the fact that both of our patients were
carriers of the same mutation in fD resulting in a
substantial lowered serum fD level, patient A
experienced multiple invasive infections, whereas
patient B did not. We think that this is largely
due to the chance that an individual encounters a
virulent bacterial strain. For instance, the Biesma
study describes three family members with a
complete factor D deficiency who did not have a
history of recurrent infections,5 and similar reports
have been published on patient with other
complement deficiencies including C5.11 Other
differences in the complement pathway proteins
could also contribute to a difference in disease
susceptibility. For patient A, significant lower
levels of C1 inhibitor, C3, C5 and vitronectin were
detected.10 In addition, and especially relevant for
complement deficiencies that can be compensated
by sufficient CP activation, nasopharyngeal
colonisation or subclinical infections induce
immunisation that would protect against
reinfection.
Besides genetic variations resulting in lowered
serum factor D levels, differences in adipose tissue
have been shown to affect serum factor D levels.
Unlike most complement proteins, which are
mainly produced by the liver, factor D is largely
produced by adipose tissue.12,13 As a result,
patients with congenital generalised
lipodystrophy have a lowered serum factor D
level.14 Wu et al. also showed factor D titration
experiments on AP activity by haemolytic and
microtitre plate assays. In both assays, a factor D
concentration- and time-dependent increase in AP
activity was observed.14
We show that fD plays a pivotal role in the AP
complement activation, which has also been
acknowledged by the pharmaceutical industry
who have multiple fD blocking or inhibiting drugs
in their pipelines for diseases that are
characterised by an over-active or uncontrolled
complement system. For example, patients with
paroxysmal nocturnal haemoglobinuria lack the
presence of complement-inhibitory proteins,
leading to intravascular erythrocyte lysis due to
uncontrolled complement activation. Inhibition of
fD by Danicopan resulted in decreased
intravascular erythrocytes lysis, but also resulted in
a substantial inhibition of AP activity,15 which
potentially increases susceptibility for infections.
Therefore, these patients are vaccinated against
N. meningitidis, H. influenzae and S. pneumoniae.
Complement activation contributes to the
defence against bacterial infections by C3b-
deposition on the bacterial surface. This facilitates
phagocytosis and forms the starting point of the
assembly of the MAC in the outer membrane. In
order to be efficient, the speed of C3b deposition
and the subsequent killing machinery should be
faster than the proliferation rate of the
bacterium. The aim of the AP is to accelerate C3b
deposition on the bacterial surface. Therefore,
absence of AP activation increases the chance for
invasive bacterial infections with species that
proliferate rapidly in the bloodstream.2–9 Here, we
show that lowered fD levels decrease AP
activation speed, which points towards a novel
type of immunodeficiency that is characterised by
an intact but too slow complement response,
which predisposes to infections with rapidly
proliferating bacteria that demand a rapidly
accelerating response of complement.
In this study, we show by a series of
experiments that the speed of AP complement
activation is considerably decreased at fD levels
< 0.5 µg mL1. These results are in line with a
dose-dependent increase in AP50 as measured by
erythrocyte haemolysis observed in experiments
performed by Biesma et al. and Hiemstra et al.3,5
In addition, we show that the widely used AP
assay based on Seelen et al.16 perfectly identifies
partial fD deficiency with clinical significance. We
also show that fD concentration affected
complement C3 deposition on the bacterial
surface in a species-specific manner. Complement
C3 deposition with fD-deficient serum, which is
entirely CP- and LP-dependent because of the AP-
pathway deficiency, differed between bacterial
species, with Nm having the highest C3 deposition
measured. For Nm, addition of only 0.09 µg mL1
fD resulted in a half maximal increase in
complement C3 deposition, indicating that for this
type of infection only very low fD levels are
needed to offer protection. Vaccination, boosting
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the CP through an increased binding of IgG to the
bacterial surface, completely compensates for the
absence of fD.
In conclusion, we show that low fD levels
(< 0.5 µg mL1) result in a more indolent
complement activation response, revealing a type
of immunodeficiency that may become clinically
overt only in the absence of sufficient antibody-
mediated CP activation and during bacterial




Tests with sera from the two siblings were performed as
part of diagnostic functional testing to assess the relevance
of the heterozygous fD mutation, in order to provide
optimal patient care and counselling.17 The protocols for
blood collection from healthy volunteers and the previously
described patient with homozygous fD mutation were
approved by the ethics committee of the Radboudumc,
Nijmegen.6 Patients and their parents gave oral informed
consent for blood sample collection. Healthy volunteers
gave written informed consent. All experiments were
carried out in accordance with local guidelines and
regulations and comply with the Declaration of Helsinki
and the Good Clinical Practice guidelines.
Exome sequencing procedure
Analysis of 386 primary immunodeficiency genes using
clinical exome sequencing was done as described
previously.18 For the gene panel analysis, a bioinformatic in
silico filter was applied to select for variants affecting 386
PID genes.19
Complement factor D ELISA
A Nunc MaxiSorp ELISA plate was coated with 1 µg mL1
mice anti-human fD (clone D10/4, Thermo Fisher Scientific,
Waltham, MA, USA) in coating buffer (0.05 M carbonate
buffer, buffer pH 9.6) and incubated overnight at 4°C. The
plate was washed 3x with wash buffer [0.1% Tween 20 in
phosphate-buffered saline (PBS)]. The ELISA plate was
blocked for 1 h with 2% Casein in PBS followed by washing
39 with wash buffer. Human fD standards (A136,
CompTech, Tyler, TX, USA) (final concentration 500 ng mL1
through 0.69 ng mL1) and patient plasma (1:2, 1:10, 1:50,
1:150 and 1:450) were diluted in PBS + 0.2% Tween
20 + 10 mM EDTA and added to the wells, incubated for
60 min at room temperature, followed by washing 39 with
wash buffer. Biotin-conjugated mouse anti-human fD (clone
J-8/1; Thermo Fisher Scientific) was diluted to 0.5 µg mL1
in PBS + 0.2% Tween 20, incubated for 60 min at room
temperature followed by washing 39 with wash buffer.
Streptavidin-Peroxidase (GE Healthcare, Freiburg, Germany)
was diluted 1000-fold diluted in PBS + 0.2% Tween 20,
incubated for 60 min at room temperature followed by
washing 39 with wash buffer. o-Phenylenediamine
(0.4 mg mL1) + 0.1% H2O2 in 50 mM phosphate-citrate
buffer pH 5.0 was added to the ELISA plate, and the
reaction was stopped after 5 min by adding 1.2 M H2SO4.
The absorbance was measured at 492 nm and at 690 nm to
control for background signal. Normal reference values for
fD are 0.96–2.13 µg mL1.
Classical and alternative pathway activity
assay
CP and AP activity analyses were based on Fredrikson
et al.20 and Seelen et al.16. For the CP analysis, a Nunc
MaxiSorp ELISA plate was coated with 120 µL 200 µg mL1
human IgG (0.05 M carbonate buffer, pH 9.6) and incubated
overnight at 4°C. For the AP analysis, a Nunc MaxiSorp
ELISA plate was coated with 8 µg mL1 Salmonella typhosa
LPS (Sigma-Aldrich, St. Louis, MO, USA) (AP) in 120 µL PBS
by drying for 2 days at 37°C. The ELISA plate was blocked
for 1 h with 1% gelatin in Tris-buffered saline (TBS). Plates
were washed 29 with wash buffer (0.01% Tween 20 in TBS)
using a microplate washer (Tecan, Durham, NC, USA).
Serum was diluted 409 (CP) in dilution buffer (10 mM Tris,
84 mM NaCl, 0.5 mM MgCl2, 2 mM CaCl2, 0.1% gelatin) or
109 (AP) in dilution buffer (10 mM Tris, 140 mM NaCl, 5 mM
MgCl2, 10 mM EGTA, 0.1% gelatin), added to the wells in
duplicate, and incubated for 60 min (CP) or 75 min (AP) at
37°C. For time-course experiments, the incubation time was
30, 45, 60 or 75 min for both AP and CP analyses. Plates
were washed 29 with wash buffer. Mouse aE11 monoclonal
anti-C5b-9 (sc-58935; Santa-Cruz Biotechnologies, Santa
Cruz, CA, USA) was diluted 1000-fold in wash buffer, added
to the wells and incubated 1 h at room temperature while
shaking at 600 rpm, followed by washing 29 with wash
buffer. Alkaline phosphatase-labelled goat anti-mouse Ig
(A7434; Sigma) was diluted 2000-fold in wash buffer, added
to the wells and incubated 1 h at room temperature while
shaking at 600 rpm, followed by washing 29 with wash
buffer. P-nitrophenylposphate (1 mg mL1) in substrate
buffer (1 M diethanolamine, 0.5 mM MgCl2 pH 9.8) was
added, and the reaction was stopped after 15–20 min by
adding 2 M NaOH. The absorbance was measured at 405 nm
using a 96-well plate reader (Tecan). Pooled human serum
was used as control. Normal reference values for AP are 67–
133%, and normal reference values for CP are 67–149%.
Wieslab Complement System Alternative Pathway ELISA
(SVAR Life Sciences, Malm€o, Sweden) was used following
the manufacturer’s instructions.
Bacterial strains and growth conditions
The non-typeable H. influenzae (NTHi) strain 11P6H was
isolated from an adult during an acute exacerbation of
COPD,21 and NTHi strain 86-028NP was isolated from a child
with chronic otitis media.22 Streptococcus pneumoniae
strain PBCN0460 (serotype 18C) was isolated from blood of
adults with bacteraemia.23 S. pneumoniae strain TIGR4
(serotype 4) is a widely used virulent laboratory isolate,24
and N. meningitidis strain H44/76 (serogroup B) and C11
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(serogroup C) are sequenced laboratory isolates.25,26 NTHi
strains were cultured overnight at 37°C + 5% CO2 on brain
heart infusion (BHI) agar plates supplemented with
1 µg mL1 hemin (Sigma-Aldrich) and 2 µg mL1 ß-
nicotinamide adenine dinucleotide (Merck, Darmstadt,
Germany) (sBHI). NTHi strains were subsequently grown in
sBHI broth to an optical density at 620 nm (OD620) of 0.6
while shaking at 250 rpm and 1 mL aliquots with 16%
glycerol were stored at 80°C for further experiments.
S. pneumoniae strains were cultured overnight at
37°C + 5% CO2 on Columbia blood agar plates (Becton
Dickinson, BD Bioscience, Franklin Lakes, NJ, USA).
S. pneumoniae strains were subsequently grown in Todd-
Hewitt broth supplemented with 5 g L1 yeast extract (THY)
at 37°C and 5% CO2 to an OD620 of 0.3 and 1 mL aliquots
with 16% glycerol were stored at 80°C for further
experiments. N. meningitidis was cultured overnight at
37°C + 5% CO2 on CG agar plates (BD Biosciences, San Jose,
CA, USA). N. meningitidis strains were subsequently grown
in GC broth at 37°C to an OD620 of 0.3 while shaking at
250 rpm and were used directly in experiments. The
number of colony-forming units (CFU) per mL was
determined by plating serial 10-fold dilutions on agar
plates.
Flow cytometric analysis
Frozen bacteria stocks were thawed, washed once with
HBSS + Ca2+/Mg2+ + 0.1% gelatin (HBSS3+) and diluted to
an OD620 of 0.1 with HBSS3+. A volume of 25 µL of bacteria
were mixed with 25 µL 10% human serum (for C3 binding)
or 10% heat-inactivated (HI) (20 min 56°C) serum (for IgG
binding) in HBSS3+ with or without reconstitution of fD
(A136; CompTech) reconstitution and incubated 0, 5, 15 or
30 min at 37°C. Complement activation was stopped by
adding 5 mM EDTA and cooling on ice. Bacteria were
pelleted by centrifugation at 3200 g and fixed for 20 min in
2% paraformaldehyde in PBS at room temperature. Surface-
bound complement C3 was detected with 1:500-diluted
FITC-labelled polyclonal goat anti-human C3 (MP
Biomedicals, Solon OH, USA). Surface-bound IgG was
detected with 1:500-diluted Fcc fragment-specific PE-
labelled AffiniPure goat anti-human IgG (Jackson
ImmunoResearch, West Grove, PA, USA). Surface binding of
C3 or IgG was determined by flow cytometry using a FACS
LSR II instrument (BD Biosciences) and expressed in mean
fluorescence intensity in arbitrary units. Data were analysed
by using FlowJo version 10.4.1. (FlowJo LLC, Ashland, OR).
Serum killing assay
Frozen NTHi stocks were thawed, washed once with PBS,
diluted to an OD620 = 0.1 in PBS and diluted 2500-fold in
HBSS3+ to obtain a concentration of ~200 000 CFU mL1.
N. meningitidis was grown fresh in GC broth at 37°C and
5% CO2 to an OD620 of 0.23, washed once with PBS and
diluted 1000-fold in HBSS3+ to obtain a concentration of
~200 000 CFU mL1. A volume of 25 µL of bacteria were
mixed with 25 µL 10% serum with or without
reconstitution of fD or with 10% HI serum and incubated
for 30 min (N. meningitidis) or 60 min (NTHi) at 37°C.
Samples were diluted 10- and 100-fold with PBS, and three
droplets of 20 µL of the undiluted, 10 and 100-fold diluted
bacteria were plated on agar plates and grown overnight
at 37°C and 5% CO2. Survival was determined by dividing
the CFU counts in NHS by the CFU count in HI-serum after
30 min (N. meningitidis) or 60 min (NTHi) incubation and
presented as percentage.
Statistical analysis
Statistical analyses were performed with GraphPad Prism
(Graphpad, San Diego, CA, USA) version 5.03 for Windows.
Differences were considered significant at P-value < 0.05.
The specific statistical tests that were used for the various
experiments are specified in the figure captions.
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